H2020Индивидуална стипендия2019–2021

PREMOTHER · PREvention of MOther-to-child Transmission of HIV and Syphilis using an Electrochemical Readout based on DNA Switches

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2019-01-07 → 2021-01-06
Финансиране от ЕС: 170 122 €
Участници: 1
Схема: MSCA-IF-EF-RI

Линиите свързват координатора с партньорите.

Накратко на български

Разработва се нов метод за бързо и точно измерване на антитела към ХИВ и сифилис директно в кръвта. Този подход помага за ранна диагностика при бременни жени, което може да предотврати хиляди смъртни случаи при новородени.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

PREvention of MOther-to-child Transmission of HIV and Syphilis using an Electrochemical Readout based on DNA Switches

Mother-to-child transmission of HIV and Syphilis causes approximately 305,000 fetal and neonatal deaths every year and leaves 215,000 infants at increased risk of dying from prematurity, low-birth-weight or congenital disease. An accurate diagnosis and a simple treatment during the first weeks of pregnancy could prevent the majority of those deaths. The PREMOTHER project aims at the development of a new technique to be used to precisely measure anti-HIV and anti-syphilis antibodies directly in whole blood, overcoming the intrinsic limitations of current laboratory-based (e.g., expensive, time-consuming) and point-of-care (e.g., qualitative, with low sensitivity and specificity) techniques. As a result, the final device should be able to provide the single-step, quantitative measurement of multiple diagnostic antibodies in less than 15 minutes, thus supporting its use at the point of care by non-specialized personnel. During the timeframe of the project several efforts towards the development of the final device have been made, however due to the year-long limitations related to the COVID-19 pandemic it has not been possible to clinically validate the performance of the device. We expect to conclude such validation in the following months as soon as the pandemic is under control. We believe that, in a near future, this new technology can be a valuable tool towards bringing personalized medicine to both high- and low-income countries.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Mother-to-child transmission of HIV and Syphilis causes approximately 305,000 fetal and neonatal deaths every year and leaves 215,000 infants at increased risk of dying from prematurity, low-birth-weight or congenital disease. An accurate diagnosis of diagnostic-antibodies and a simple treatment during the first weeks of pregnancy could stop all those deaths. Here, I propose the development of a new technique to be used to measure antibodies directly in whole blood. These will combine the multiplexed (i.e., multiple tests in parallel on one sample), quantitative performance of laboratory-based tests with the portability and low-cost of point-of-care tests. As the first step, I will design, optimize and test nanometer-scale, DNA-based “switches” that undergo a dramatic change in conformation (closed/open) upon recognizing its target antibody. I will use this conformational change to generate a large, easily measurable electronic (electrochemical) signal, which I will then employ in and validate as laboratory-scale, single-test devices using both purified antibodies and authentic human samples. I will then integrate the set of sensors exhibiting good clinical performances into a single, paper-based microfluidic sample handing device (similar to the home pregnancy test) to generate a low-cost platform capable of measuring multiple diagnostic antibodies in a single finger-prick blood sample. The final and main goal in the DNA-SPADE project is the development of a working prototype diagnostic device, which I will design accordingly to suggestions/inputs from a variety of possible final users (such as nurses and doctors).

Оригинален текст от CORDIS (на английски).

Участници

FUNDACIO INSTITUT CATALA DE NANOCIENCIA I NANOTECNOLOGIA · BELLATERRA (BARCELONA)КоординаторИспания